Standout Papers

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALC... 2016 2026 2019 2022 364
  1. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial (2016)
    J.F.R. Robertson, Igor Bondarenko et al. The Lancet

Immediate Impact

56 standout
Sub-graph 1 of 22

Citing Papers

Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
2024 Standout
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
2024 Standout
2 intermediate papers

Works of Servando Cardona‐Huerta being referenced

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
2016 Standout

Author Peers

Author Last Decade Papers Cites
Servando Cardona‐Huerta 480 71 237 359 39 894
Reginald P. Pugh 578 51 219 269 34 1.1k
Jeffrey W. Prichard 288 123 142 288 38 899
F Badellino 384 75 324 411 65 1.0k
Antonio Febbraro 636 78 239 310 56 1.2k
Yeu‐Tsu N. Lee 609 92 175 338 56 1.0k
Elias Sanidas 292 68 185 256 43 913
Jürgen Breul 257 152 121 601 43 956
Joanna Dewar 491 68 219 384 22 935
Hossein Saboorian 445 53 365 381 24 1.1k
Véronique Verrièle 387 43 371 227 34 898

All Works

Loading papers...

Rankless by CCL
2026